Verified report from bloomberg.com
NewsMatic brief
Adarx Pharmaceuticals Inc., a late-stage developer of gene therapies, raised $446.3 million in an upsized initial public offering that priced at the top of its marketed range.
NewsMatic provides a concise source-linked brief. The protected full report and continuing updates remain with the original publisher.
Read the full report at bloomberg.com →Related coverage
Meta Platforms Inc. is finally seeing the stock breakout that beleaguered bulls had been banking on.
Read on NewsMatic →
India’s market regulator will allow its $463-billion portfolio management industry to invest in overseas securities and undertake short selling in equity options for the first time as part of a massive overhaul of rules.
Read on NewsMatic →
US stocks rebounded from earlier losses on a report that the US and Iran were discussing a phased deal to reopen the Strait of Hormuz, pulling oil down from the peak hit earlier in the session.
Read on NewsMatic →
European stocks retreated for a second day as oil prices spiked and global bonds sold off, with the average yield rising to levels not seen for almost two decades.
Read on NewsMatic →
Subdued retail demand for the IPO and the gray market indicating a gain of about 2%-3% suggest that a blowout first-day pop is unlikely.
Read on NewsMatic →
The Nikkei stock benchmark gained after a three-day holiday as Tokyo’s market caught up with a global AI-led rally. Climbing bond yields and a rise in oil prices weighed on broader risk appetite, however.
Read on NewsMatic →
